malaria and sickle cell disease treatment Market

The malaria and sickle cell disease treatment market is expected to grow from US$ 4,457.15 million in 2022 to US$ 29,179.60 million by 2030; it is estimated to grow at a CAGR of 26.5% from 2022 to 2030.

The market for malaria and sickle cell disease treatment is growing due to the increasing prevalence of malaria and sickle cell disease and rising government initiatives to raise awareness about malaria and SCD. However, factors such as a counterfeit antimalarial drug and subsequent drug resistance are restraining the market growth.  

Antimicrobial resistance can put the public at risk of many diseases, such as malaria. To overcome this challenge, the R&D of new medicines is considered the best strategy; as a result, the antimalarial and SCD drug/vaccine pipeline is becoming increasingly robust. Public-private partnerships are accelerating research activities related to the treatment of malaria and sickle cell disease. For instance, Medicines for Malaria Venture (MMV), a nonprofit organization, works with numerous pharmaceutical companies to reduce the burden of malaria by developing novel treatment options.

A few antimalarial and SCD drugs/vaccines that are under clinical development are mentioned in the table below:

Malaria Drugs/Vaccine/Compounds Under Clinical Development

Source: Company Website, The Insight Partners Analysis

Sickle Cell Disease Drugs/Vaccine/Compounds Under Clinical Development

Source: Company Website, The Insight Partners Analysis

Therefore, the growing number of antimalarial and SCD drugs/vaccines that are under clinical development are expected to boost the market growth in the future.

The report segments the malaria and sickle cell disease treatment market as follows:

The malaria and sickle cell disease (SCD) treatment market is segmented on the basis of treatment, route of administration, distribution channel, and geography. Based on treatment, the market is divided into malaria and sickle cell disease. In terms of route of administration, the malaria and sickle cell disease (SCD) treatment market is divided into oral and parenteral. Based on distribution channel, the market is categorized into direct tender, hospital pharmacies, retail pharmacies, online pharmacies, and others. By geography, the malaria and sickle cell disease treatment market is segmented into North America (the US, Canada, and Mexico), Europe (the UK, Germany, France, Italy, Spain, and Rest of Europe), Asia Pacific (China, Japan, India, Australia, South Korea, and Rest of Asia Pacific), the Middle East & Africa (Saudi Arabia, the UAE, South Africa, Kenya, Tanzania, Rwanda, Nigeria, Ghana, Uganda, Angola, Cameroon, Senegal, Zambia, and Rest of the Middle East & Africa), and South & Central America (Brazil, Argentina, and Rest of South & Central America).

Route of Administration-Based Insights

By route of administration, the malaria treatment market is bifurcated into oral and parenteral. In 2022, the oral segment held a larger market share, and the parenteral segment is estimated to record a faster CAGR during 2020–2030. Oral drug delivery is the most ideal and suitable route of drug administration as it offers high patient compliance, non-invasiveness, least sterility constraints, cost-effectiveness, flexibility in the design of dosage form, and ease in the manufacturing process. Benefits such as ease of administration and long-term cost efficiency are the major factors fueling the adoption of oral drugs.

Distribution Channel-Based Insights

Based on distribution channel, the malaria and sickle cell disease (SCD) treatment market is segmented into direct tender, hospital pharmacies, retail pharmacies, online pharmacies, and others. The direct tender segment held the largest market share in 2022. A tender is an offer to do specific duties or provide items for a fixed amount. In the first step of a tender procedure, contractors will be asked to submit sealed bids for construction or to offer particularly planned services or products within a specific time limit. The e-tendering procedure in India is designed to ensure that work for the government or a specific client is completed in a timely manner.

A few of the major primary and secondary sources referred to while preparing the report on the malaria and sickle cell disease treatment market are the World Health Organization (WHO), the US Census Bureau, and CDC, among others.